BGC-20-1531 free base
Modify Date: 2024-01-04 19:10:59
BGC-20-1531 free base structure
|
Common Name | BGC-20-1531 free base | ||
|---|---|---|---|---|
| CAS Number | 736183-35-0 | Molecular Weight | 492.54 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H24N2O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BGC-20-1531 free baseBGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1]. |
| Name | BGC-20-1531 free base |
|---|
| Description | BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1]. |
|---|---|
| Related Catalog | |
| Target |
EP4:3 nM (Ki) |
| In Vitro | BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb = 7.8) and meningeal (pKb = 7.6; Ki = 3 nM) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries[1]. |
| In Vivo | BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1]. Animal Model: Beagle dogs[1] Dosage: 1-10 mg/kg Administration: I.v. Result: Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow. |
| References |
| Molecular Formula | C26H24N2O6S |
|---|---|
| Molecular Weight | 492.54 |